---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097054"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:14.745679+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026

## Summary
- Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.
- Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.
- PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.
- PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.
- Outstanding shares: 58,942,243 as of August 14, 2024.

## SEC filing metadata
- accession: 0000950170-24-097054
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/0000950170-24-097054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/pyxs-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097054
- JSON: https://secwatch.observer/filing/0000950170-24-097054.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.